688331 荣昌生物
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)-20.700-54.148-35.907-23.7067.847
总资产报酬率 ROA (%)-7.923-26.633-26.170-19.6236.675
投入资产回报率 ROIC (%)-9.269-31.295-30.278-22.3017.336

边际利润分析
销售毛利率 (%)84.06080.36277.43264.76695.175
营业利润率 (%)-40.180-84.786-138.651-128.90021.245
息税前利润/营业总收入 (%)-36.805-81.479-140.043-138.15418.503
净利润/营业总收入 (%)-40.946-85.526-139.547-129.36419.368

收益指标分析
经营活动净收益/利润总额(%)100.047102.862102.567112.85863.826
价值变动净收益/利润总额(%)0.9750.188-0.462-1.2120.000
营业外收支净额/利润总额(%)1.8720.8650.6420.359-9.692

偿债能力分析
流动比率 (X)1.0591.0511.9763.6633.758
速动比率 (X)0.8070.7481.3183.0673.300
资产负债率 (%)59.70363.87837.82317.28717.138
带息债务/全部投入资本 (%)50.68354.41224.6532.1684.113
股东权益/带息债务 (%)92.28478.335295.1394,368.3852,265.230
股东权益/负债合计 (%)67.49456.550164.386478.465483.513
利息保障倍数 (X)-8.888-20.133282.44815.718-21.383

营运能力分析
应收账款周转天数 (天)60.55371.40583.05747.6380.583
存货周转天数 (天)668.815747.907931.109531.299906.380